Medical/Pharmaceuticals
Daewoong Pharmaceutical Publishes Results of First Clinical Study of SGLT-2 Inhibitor 'Enavogliflozin' for Canine Diabetes
SEOUL, South Korea, June 1, 2021 /PRNewswire/ -- Daewoong Pharmaceutical (CEO Sengho Jeon) announced that the results of an investigator-initiated clinical study on the effect of Enavogliflozin, originally developed as Type II Diabetes Treatment forhumans, on treating canine diabetes were publish...
2021-06-01 21:00
2293
GenScript ProBio and Neoletix signed a letter of intent on clinical and commercial production of recombinant human coagulation factor VIII
NANJING, China, June 1, 2021 /PRNewswire/ -- On June 1st 2021, GenScript ProBio and Neoletix (Beijing) Biotechnology Co., Ltd. (hereinafter referred to as Neoletix) signed a letter of intent on cooperation for clinical and commercial production of human coagulation factor VIII. GenScript ProBio s...
2021-06-01 21:00
1970
BioVaxys And Bioproduction Partner Bio Elpida Begin Construction Of GMP Facility To Produce Clinical Supply For Planned Ovarian Cancer Vaccine Study
VANCOUVER, BC and LYON, France, June 1, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (US OTCQB: BVAXF)("BioVaxys" or "the Company") is pleased to announce that its bioproduction partner Bio Elpida of Lyon, France, has initiated construction of a new Good Manufacturing Prac...
2021-06-01 20:00
4983
Neurophth Therapeutics and Hopstem Biotechnology Announce Strategic Partnership to Develop Human Induced Pluripotent Stem Cell-Derived Therapies for the Treatment of Ocular Diseases
HOUSTON and SAN DIEGO, June 1, 2021 /PRNewswire/ -- Neurophth Biotechnology Ltd., a fully-integrated genetic medicines company developing AAV-mediated gene therapies for the treatment of ocular diseases, and Hopstem Biotechnology, the leading human induced pluripotent stem cell (hiPSC) and neural...
2021-06-01 19:50
1649
Occlutech takes important step towards approval in China
SCHAFFHAUSEN, Switzerland, June 1, 2021 /PRNewswire/ -- Occlutech AG ("Occlutech" or the "Company") today announces that the planned recruitment of 180 patients has been reached in the Company's trial inChina for its ASD Occluder. The Occlutech ASD Occluder is used in the treatment of Atrial Sept...
2021-06-01 19:02
2682
Positive FDA meetings enable Neuren to proceed with INDs for three Phase 2 trials
Highlights: * Clear and constructive guidance received from pre-IND meetings with the FDA Office of Neuroscience for Phase 2 clinical trials of NNZ-2591 in Phelan-McDermid, Angelman andPitt Hopkins syndromes * Positive outcome is an important milestone that enables Neuren to proceed with IND...
2021-06-01 18:00
1727
Scripps Research Institute testing shows Viraleze highly active against UK COVID strain
MELBOURNE, Australia, June 1, 2021 /PRNewswire/ -- Australia's Viraleze anti-COVID nasal spray is active against the highly infectious UK variant of SARS-CoV-2, the virus that causes COVID-19, reducing infectivity of the virus by >98%, it was announced today in a major development for the product...
2021-06-01 17:30
2186
Australia's original prolonged-release melatonin now available over the counter at pharmacies
MAIN POINTS * Circadin® prolonged-release melatonin is now available without prescription1 * Circadin® is clinically proven in people aged 55 and over2 to help them fall asleep quicker, sleep better, wake refreshed, and in turn improve quality of life3 * Circadin® mimics the effect of the b...
2021-06-01 17:05
2385
Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis
Agreement Renews Successful Global Collaboration That led to Several Groundbreaking Therapies in Multiple Disease Areas KHK4083 Depletes OX40-Expressing T cells Associated with Atopic Dermatitis and Several Other Inflammatory Diseases Moderate-to-Severe Atopic Dermatitis Affects Nearly 30 Mill...
2021-06-01 16:00
5608
100th Elekta Unity MR-Linac goes to St George's Hospital in New Zealand
CHRISTCHURCH, New Zealand, June 1, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announces that St George's Hospital inChristchurch, New Zealand, has ordered an Elekta Unity MR-Linac, making it the 100th device sold since introduction. Today, the innovative radiation therapy device is found in 14 count...
2021-06-01 15:07
5301
AVATAMED sets up Joint Service Lab with A*STAR's Institute of Molecular and Cell Biology to offer Precision Oncology Services
SINGAPORE, June 1, 2021 /PRNewswire/ -- AVATAMED (www.avatamed.com
2021-06-01 09:00
2824
Innovent Biologics and AnHeart Therapeutics Jointly Announce Exclusive License Agreement for Taletrectinib in Greater China
SAN FRANCISCO and SUZHOU, China, June 1, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major disease...
2021-06-01 08:00
5363
Introduce the World's First Biomedical Application Mask that Revolutionizes Face Mask to Resist Aerosol Transmission
TAIPEI, May 31, 2021 /PRNewswire/ -- Taer Innovation has won design awards including Good Design award from 2012 to 2014 Golden Pin Design award, Taiwan Excellence award in 2014 and Computex d&I award in 2014 for their products.The companyfocuses on medical innovation and technology. The company'...
2021-05-31 23:00
2365
PENTAX Medical and Vedkang Establish Endoscopic Therapeutics Joint Venture
TOKYO, May 31, 2021 /PRNewswire/ -- PENTAX Medical (a division of HOYA Group) and Jiangsu Vedkang Medical Science and Technology Co., Ltd (Vedkang) today announced the establishment of a joint venture- PENTAX Medical Therapeutics ( Jiangsu) Co., Ltd.(*) to develop single-use therapeutics products ...
2021-05-31 21:00
3048
PolyU develops biomimetic nanosheet for cancer therapy and imaging
HONG KONG, May 31, 2021 /PRNewswire/ -- A research team from the Department of Applied Biology and Chemical Technology (ABCT) of The Hong Kong Polytechnic University (PolyU) has developed a novel type of biomimetic nanosheet with a multi-modal imaging function, which can track tumour development ...
2021-05-31 19:42
3157
RhoVac Confirms Forecast - BRaVac Phase IIb study recruitment to close in Quarter 3 2021
STOCKHOLM, May 31, 2021 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today,May 31, 2021, that it confirms its previous forecast to be able to conclude recruitment for its multi-centre BRaVac Phase IIb study in Quarter 3 2021. Also, all new US clinics hav...
2021-05-31 19:33
2227
Samsung Biologics to add mRNA vaccine drug substance manufacturing suite to expand portfolio of services
* Samsung Biologics, a global leading CDMO, will add mRNA vaccine DS production capability to its existing facility by the first half of 2022 * The addition will enable Samsung Biologics to provide end-to-end mRNA vaccine manufacturing services from bulk drug substance to aseptic fill/finish ...
2021-05-31 19:00
3127
Moleac Announces US FDA Approval of IND Application for Phase 1 Study of MLC1501 Programme in Post-Traumatic Brain Injury Recovery
SINGAPORE, May 31, 2021 /PRNewswire/ -- Moleac, a biopharmaceutical company based inSingapore, announced the approval by the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for MLC1501 in traumatic brain injury (TBI). Moleac is dedicated in finding, devel...
2021-05-31 18:33
3061
Mindray Defines Future of Imaging Technologies with New General Imaging, Women's Healthcare and Cardiology Ultrasound Solutions
SHENZHEN, China, May 31, 2021 /PRNewswire/ -- Mindray (SZSE: 300760), a global leading developer and provider of medical devices and solutions, has announced the launch of its new General Imaging, Women's Healthcare, and Cardiology ultrasound solutions onMay 28, 2021. Underpinned by the theme "In...
2021-05-31 10:15
8888
Hummingbird Bioscience Announces Publication of Abstract on Anti-VISTA Antibody HMBD-002 at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
* HMBD-002 is the only IgG4 isotype anti-VISTA antibody currently in development * HMBD-002 is anticipated to enter a Phase 1 clinical trial in 2021 HOUSTON andSINGAPORE, May 31, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing pr...
2021-05-31 10:00
2353
Week's Top Stories
Most Reposted
Visa and Trip.com Group Ink Strategic Collaboration, Enabling Consumers to Chase Their Passions Through Travel
[Picked up by 309 media titles]
2026-05-19 18:10
Two-day Global Prosperity Summit 2026 officially opens
[Picked up by 308 media titles]
2026-05-19 23:59
Two‑day Global Prosperity Summit 2026 concludes successfully
[Picked up by 303 media titles]
2026-05-21 22:13
Hyundai Motor Group to Pioneer Hong Kong's Hydrogen Economy, Accelerating Asia-Pacific Expansion
[Picked up by 290 media titles]
2026-05-18 15:30
Autonomous AI marketing platform Protaigé launches with Maia, the world's first AI Account Director that operates within the flow of work
[Picked up by 280 media titles]
2026-05-20 09:15Most Read
/C O R R E C T I O N -- The American Chamber of Commerce in Singapore (AmChamSG)/
2026-05-21 12:14
5774
NYSE Content Update: Armada Raises $230 Million, Boosts Valuation to $2 Billion
2026-05-19 21:02
5771
Scienjoy Holding Corporation Reports Unaudited First Quarter 2026 Financial Results
2026-05-21 20:30
5708
NYSE Content Update: Lincoln International Pops by 13% in First Day of Trade
2026-05-21 21:04
5578
